$AEHR People are waking up to Aehr Test Systems after yet another phenomenal earnings. They posted a triple beat, trouncing EPS expectations, while revenue exploded. In addition to the results, the earnings call itself was their best I've ever heard over the past 5 years. Here's what stood out to me. GUIDANCE Aehr raised guidance to $150m for the year. If you look at revenue in Q1 ($33m) and their effective backlog, most (if not all) which will be delivered in this fiscal year, that gets them to $142.3m. When asked by an analyst on how conservative these figures seemed, CEO Gayn Erickson said, "We just thought 150 is a pretty nice, clean number for us to be conservative at this point." This is more than just being conservative, and more than just sandbagging, implying that they will only receive and deliver $7.7m beyond the backlog and realized revenue through next June! Let's pretend they don't get a single new order for units. Servicing revenue alone likely gets them to $150m. On top of that, contactors revenue is only partly built into the backlog. Yet the customer that is ordering tons of Sonoma units, and "Importantly, the customer forecast that this second processor will ultimately reach higher production volumes than its first processor currently in production on Sonoma." That's upside. Given the cadence of new orders and what they said regarding their lead Hyperscaler, there's a decent chance we see $AEHR land on around $200m on the year. While that doesn't sound impressive in isolation, it represents a 4x over the prior year's numbers. LINES IN THE WATER There are a number of whales that are circling, and many are massive. The most significant and nearest one to landing is probably $AMD or $NVDA, as Gayn explicitly ruled out the ASIC guys last October, and the description and ramp can match either. This engagement went from potential, to showing fantastic results during engineering qualifications last quarter (expanding to two other product lines for those tests), to an order for one unit put in the company's OSAT production line. We won't see any orders from this company until next year at earliest, and revenue might not be realized from them until the 2nd half of next year, but this would instantly become their largest client, as these are the premium Fox-XP systems, which command higher prices and better margins. Gayn has said in the past when this wasn't going well (an issue with the clock speed a couple of quarters ago). And he has been clear when something is pretty far away or uncertain. There is no guarantee here, but from the context of the earnings call, it sounds like they are engaged with both $AMD and $NVDA, probably all (or all but one) Hyperscaler, and multiple other customers. They won't win them all, but per Gayn, "But you pick off one, two, three high runners, and these are big numbers. You get a customer who's saying, 'I would like to consider this for all my devices or most of my devices or every device you cold do it,' and all of a sudden, it becomes the biggest deal you've ever looked at before. THEY DID THE MATH FOR US Gayn laid out the TAM opportunity in the AI processors space. For every 1m units shipped, the production line would require 5-10 of Aehr's systems, delivering 45-90 wafers of capacity (each system configured for AI processor tests has up to 9 racks). That comes to $35-$70m for each million units of production. Gayn stated AI accelerator markets in '27 are 25m units across $NVDA, $AMD, and the ASICs guys, and CPUs are 2x this. The customer mentioned above, if landed, would generate around $250m in FY '27 revenue for the company alone. This is why Aehr keeps expanding production capacity and outsourced production of their PLBI Sonoma units to an OSAT. They HAVE to demonstrate the ability to deliver, and there is plenty of room for some massive orders in the queue. Per Gayn, "I am pressing on the team to be able to put a lot more than that in place for the following year or maybe even pull in. There are ways that we are working with our subcons." THE COMPETITION / MOAT Three notes on competition. One, they indicated that their first WLBI customer provided a lot of visibility into the space, and these guys all know each other. "They, we believe, have been very visible to other customers who are aware of it. Either they walk by it at the OSATs or they're just aware of it. There have been even some rumors about them going up and publicly talking about it that I'm not ready to verify yet right now... they all feed on each other, not dissimilar to some of the stuff that was going on in SiC before, obviously, the EVs sort of just went quiet, right? We were starting to win EVERYTHING." Second, on $TER moving upstream to PLBI, it's competition for sure, but not quite in the way that the market fears. Gayn gave a lot of technical details on this, from voltage, to how the burn-in process isn't quite what Teradyne's Titan unit is made for, to SLT burn-in (which is not great), to throughput (1/4th a wafer at a time with 9 wafers in parallel vs one device at a time). "We are playing with a different set of deck of cards, if you will, than our competitors are." Lastly, they're still really the only game in town for WLBI testing. NEW TECHNOLOGY This is the first I have heard of the "super-duper Wafer Paks" (they call them Die temperature control - DiTC, but I like Larry's affectation). "It has the ability to actually independently manipulate the thermals of each of the die under test at the wafer level, which is nuts. People have never even contemplated that before. It's integrated into our WaferPak and custom-designed for each of the wafers under test." Beyond just thermal runway avoidance, which Gayn talked about, this is going to improve ATE outcomes tremendously. "The die do not all burn in and have the same leakages, so they are all going to generate different power and different heat, self-heating. The way people will do that is they will look at the hottest die and control the temperatures on that one to avoid it from going into thermal runaway. But when they do that, the coldest die is not at the burn-in condition. And their customers are like, "Well, what are we going to do?" So, that device is actually not burnt in optimally, so that infant mortality or that failure rate will sneak through all the way to the data center." Honestly, this would have sounded like science fiction two years ago. This will be in production at the start of the year. People question how a little company like this can stay ahead of the giants (Advantest and Teradyne), but their R&D continues to strengthen their moat. This has tremendous upside with fantastic execution and a very clear roadmap. Yes, I added shares.